Strategic collaborations Evotec’s multi-modality end-to-end drug discovery and development model offers opportunities to position integrated R&D services as a single-partner solution for pharma and biotech clients seeking faster timelines and reduced risk across discovery to manufacturing.

AI and data With a dedicated in silico and AI leadership appointment and a data-driven approach, highlight opportunities to provide scalable AI/ML-enabled target discovery, predictive analytics, and decision-support tools to accelerate candidate selection and de-risk programs.

Dermatology alliance The Evotec–Almirall collaboration and recent preclinical dermatology nomination indicate a pipeline strength in immune-mediated skin diseases, suggesting cross-sell of dermatology-focused target discovery, compound optimization, and translational biology services to other dermatology players.

Public health funding Gates Foundation TB grants demonstrate Evotec’s capacity to execute funded, high-priority infectious disease programs; leverage this to pursue government and foundation-backed programs or co-development deals in TB, other antimicrobial resistance areas, and global health initiatives.

Funding and governance Recent convertible bond activity and board expansions signal ongoing growth and investor-backed expansion; align sales outreach to late-stage R&D outsourcing needs, CRO/CDMO-like services, and scalable manufacturing support as clients seek resilient, well-funded partners.